Cerebral amyloid angiopathy (CAA) has been gaining attention over the past few years, thanks to increased research in the field. Professor David Werring (UCL Institute of Neurology, Queens Square, London) discusses the recent advances in biomarkers analysis, as well as providing an overview of the clinical spectrum of CAA. Read the full paper here: http://jnnp.bmj.com/content/early/2017/08/26/jnnp-2016-314697